Search results
Results from the WOW.Com Content Network
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 Inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Pembrolizumab (Keytruda, formerly MK-3475 and lambrolizumab) was developed by Merck and first approved by the Food and Drug Administration in 2014 for the treatment of melanoma. It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. In 2017, it became the first immunotherapy drug approved for ...
Nearly a quarter of patients who received Merck & Co's immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a ...
Merck's top-selling drug Keytruda helps the body's own immune system fend off cancer by blocking a protein called PD-1. It has been approved to treat more than ten kinds of cancer.
The FDA approves Merck's (MRK) Keytruda for the treatment of adult patients with relapsed or refractory cHL who progress after frontline therapy.
This article needs more reliable medical references for verification or relies too heavily on primary sources, specifically: Unsourced list of side effects, needs references. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed
Merck's (MRK) label expansion application for Keytruda in combination with Pfizer's Inlyta for the first-line treatment of renal cell carcinoma gets approval in Europe.